Keywords: Abbott Labs, M&A, Piramal, India, Branded generics, Emerging markets

Abbott Labs to buy Piramal domestic formulation business for $3.72 billion; to become number one drugmaker in India

Article | 21 May 2010

Print This

Fooling all the speculators, US health care major Abbott Laboratories has declared its intention to acquire Indian branded generics drugmaker ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in